VIDD’s Division strategy involves methodically uncovering findings in the laboratory that inform prevention studies in the clinic. Advanced statistical methods are used to analyze our experiments and reveal practical insights that guide patient care. Our advanced computational analyses help scientists and policymakers predict and prevent future outbreaks.
VIDD’s research encompasses an international scope, seeking preventions and cures for globally significant diseases including HIV, Ebola, tuberculosis, malaria and West Nile Virus. We also maintain robust research efforts to prevent and treat the most dangerous infections for cancer patients and people with weakened immune systems. These include cytomegalovirus, respiratory syncytial virus and multiple herpes viruses.
Using mathematical modeling, computational biology, epidemiology and statistics, scientists within our BBE Program determine how infectious diseases are spread and contained. Our researchers collaborate across multiple research areas to incorporate biostatistics, bioinformatics and population modeling throughout vaccine design, development, evaluation and deployment.
The Bedford lab studies the dynamics of virus populations to understand how strains evolve and spread throughout the world. The team is particularly interested in how viruses mutate in response to host immune responses as well as the factors that make certain strains more virulent and infectious.
The Chen group employs biostatistics, bioinformatics, epidemiology, and mathematical modeling to answer questions on human infectious disease processes and prevention.
The Fong group uses biostatistical modeling and computational methods to analyze the effectiveness of vaccine candidates in clinical trials. The team collaborates with clinical research teams striving to eliminate HIV, dengue and cholera.
The Gilbert Group researches the statistical design and analysis of HIV vaccine efficacy trials, with emphasis on assessing immune correlates of vaccine-induced protection. Though focused on HIV vaccine trials, their research contributes to general areas of statistical methods research including surrogate endpoint assessment, causal inference, survival analysis, and efficient randomized trial design.
The Gottardo Lab develops statistical methods and software tools for the analysis of high throughput biological data with an emphasis on immunology and vaccine research. In collaboration with bench scientists and clinicians, they investigate severe diseases such HIV, malaria and cancer, to ultimately help develop vaccines and/or a cure.
The Halloran Group researches study designs and analytic methods for evaluating vaccines in populations. Research includes developing new methods as well as applying existing methods to novel applications. Going beyond the direct protective effects, they use a variety of analytic methods to understand the indirect and overall effects of vaccination programs.
The Huang Group develops statistical methods for design and analysis of biomarker studies for disease screening, surrogate endpoint identification and treatment selection in cancer and infectious diseases. They study how to efficiently select biomarkers among high-dimensional candidates and derive marker-based individualized rules, using data from randomized trials and observational studies.
Learn more about the research within Biostatistics, Bioinformatics and Epidemiology through these faculty profiles:
Scientists in our IVD Program aim to gain a fundamental understanding of the immune system, so we can create effective vaccines against serious global diseases. Our ultimate goal is to create vaccines that induce broader, more effective responses against infectious diseases. We also work to develop novel therapies for cancer, HIV, tuberculosis, malaria and other related infections. Researchers in IVD pursue investigations in the molecular underpinnings of immune regulation, vaccine immune monitoring and HIV vaccine and adjuvant design.
The HOPE Group (HIV Outcomes, Prevention and Epidemiology) focuses on interventions among African women to prevent mother-to-child HIV transmission via breastfeeding, and on trials of prophylactic HIV vaccines through the HIV Vaccine Trials Network (HVTN). The lab also conducts clinical studies and research in non-human primates and antiretroviral treatment to prevent onward HIV transmission in Peru.
The Hladik Lab conducts laboratory studies and uses systems biology tools to understand the interplay between pathogens, the mucosa and medical interventions. They focus on preventing and treating sexually transmitted diseases, especially HIV.
The Kublin Lab studies the role of the microbiome in vaccine responses, with a focus on how specific microbes and their metabolites modulate host innate and adaptive immune responses. Their work includes developing discrete microbial consortia to manipulate vaccine responses in gnotobiotic mouse models, as well as investigating microbiome and immunogenicity data from HIV, malaria, and TB clinical trials.
The Lund Lab investigates the basic mechanisms of immunity in the context of viral infection. They also investigate the immune correlates of protection from HIV infection among exposed seronegative individuals, and the potential immune modulatory effects of using pre-exposure prophylaxis.
The McElrath Lab applies multi-disciplinary and cross-platform approaches to their studies on HIV, malaria and tuberculosis vaccines, partnering with multiple organizations in various countries.
The McGuire Lab studies antibody response to natural infection with viral pathogens of public health importance. Through increased knowledge of protective antibody responses to viral antigens, they design and test safe and effective vaccines.
The Newell lab develops and applies novel methods for identifying and characterizing antigen-specific human T cells in the context of cancer and chronic infection, with the goal of identifying specific and accurate biomarkers of human health and disease.
The Prlic laboratory primarily studies T cell and innate-like T cell responses in mucosal tissues, with a particular interest in understanding how these cells function during infections and cancer occurrences. By understanding the molecular basis of cell activation and differentiation, they hope to learn how to manipulate the cells for therapeutic purposes and to improve human health.
The Stamatatos Lab investigates the activation, survival and maturation of B cell clonal lineages, and develops new immunogens and immunization regimens to target these lineages in vivo. The lab employs diverse experimental approaches, with work spanning the pre-clinical stage to clinical evaluation of candidate vaccines.
The Strong Lab investigates translational biophysics, structural molecular immunology and vaccinology. They apply biophysical approaches to understand the recognition mechanisms of innate and adaptive immunoreceptors from a molecular perspective, ultimately furthering vaccine development and engineering targeted immunotheranostics.
The Taylor Lab studies the mechanisms limiting the generation of a protective B cell response using their recently developed enrichment method. These approaches allow for the phenotypic and functional analysis of naive and activated B cells, leading to increased knowledge in effective vaccine design.
The Warren Lab focuses on cancer immunology, with a particular interest in the cellular and molecular mechanisms that mediate cancer regression after immune-based therapy. They frequently use preclinical models to study the interaction of human cancer with the immune system.